Bevacizumab-associated gastrointestinal perforation.
Chau
Ian
I
Cunningham
David
D
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology; D000068258:Bevacizumab; D004359:Drug Therapy, Combination; D005767:Gastrointestinal Diseases / Q000209:etiology; D041981:Gastrointestinal Tract / Q000187:drug effects; D006801:Humans; D007416:Intestinal Perforation / Q000209:etiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab